Barinthus Biotherapeutics has a quick ratio of 6.05. It generally indicates good short-term financial strength.
The historical rank and industry rank for Barinthus Biotherapeutics's Quick Ratio or its related term are showing as below:
STU:2AB'
s Quick Ratio Range Over the Past 10 Years
Min: 2.82 Med: 11.15 Max: 38.6
Current: 6.05
During the past 7 years, Barinthus Biotherapeutics's highest Quick Ratio was 38.60. The lowest was 2.82. And the median was 11.15.
STU:2AB's Quick Ratio is ranked better than 65.23% of 1412
companies
in the Biotechnology industry
Industry Median: 3.6
vs STU:2AB: 6.05
Barinthus Biotherapeutics (STU:2AB) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Barinthus Biotherapeutics Quick Ratio Related Terms
Barinthus Biotherapeutics Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:2AB vs VTGN, PSTV, PVCT: Quick Ratio Comparison
For the Biotechnology subindustry, Barinthus Biotherapeutics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Barinthus Biotherapeutics Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Barinthus Biotherapeutics's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Barinthus Biotherapeutics's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Barinthus Biotherapeutics's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Barinthus Biotherapeutics (STU:2AB) has a Quick Ratio of 6.05 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Barinthus Biotherapeutics and its competitors. This is 46% below median its historical median of 11.15. Over the past decade, Barinthus Biotherapeutics' Quick Ratio has ranged from 2.82 to 38.60. According to the industry distribution chart, Barinthus Biotherapeutics ranks #491 out of 1412 companies in the Biotechnology industry, placing it in the top 34.8%.
Is Barinthus Biotherapeutics' Quick Ratio too high?
Barinthus Biotherapeutics' current Quick Ratio of 6.05 is 46% below median its 10-year median of 11.15. Over the past 10 years, this metric has ranged from a low of 2.82 to a high of 38.60. The Biotechnology industry median Quick Ratio is 3.60. Barinthus Biotherapeutics' value of 6.05 is 68.1% above this industry median. Based on the distribution chart, Barinthus Biotherapeutics ranks #491 out of 1412 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Barinthus Biotherapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Barinthus Biotherapeutics' Quick Ratio compare to VTGN and PSTV?
According to the Biotechnology industry distribution chart, Barinthus Biotherapeutics ranks #491 out of 1412 companies for Quick Ratio. This puts Barinthus Biotherapeutics in the upper half of its industry. The industry median Quick Ratio is 3.60. Barinthus Biotherapeutics' value of 6.05 is 68.1% above this benchmark. Historically, Barinthus Biotherapeutics' own Quick Ratio has ranged from 2.82 to 38.60 over the past decade. While the company's 10-year median is 11.15 vs. the industry median of 3.60, Barinthus Biotherapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,412 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Barinthus Biotherapeutics's current Quick Ratio of 6.05 is 68.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Barinthus Biotherapeutics and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Barinthus Biotherapeutics's current Quick Ratio is 6.05, which is 46% below median its own 10-year median of 11.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Barinthus Biotherapeutics stock overvalued right now?
Barinthus Biotherapeutics (STU:2AB) has a current Quick Ratio of 6.05. The stock's GF Value™ is €0.94, compared to a current price of €0.57 — trading 39.9% below its estimated fair value. The current Quick Ratio is 6.05, which is 46% below median its 10-year median of 11.15 and 68.1% above the Biotechnology industry median of 3.60. Barinthus Biotherapeutics' overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Barinthus Biotherapeutics (STU:2AB), the current Quick Ratio is 6.05 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Barinthus Biotherapeutics (STU:2AB) Overvalued in 2026?
Based on GuruFocus' analysis, Barinthus Biotherapeutics stock appears to be undervalued.
The current stock price of €0.57 is trading 39.9% below its estimated GF Value™ of €0.94.
Key valuation signals for STU:2AB:
Quick Ratio: 6.05 (46% below median its 10-year median of 11.15)
GF Value™: €0.94 vs. price of €0.57 (39.9% below fair value)
Industry Position: 68.1% above the Biotechnology median (#491 of 1412)
No single metric tells the full story. See the STU:2AB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.
14GF Score
Get the complete analysis for STU:2AB
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:2AB has been successfully added to your 
